ONCOLOGY, NUCLEAR MEDICINE AND TRANSPLANTOLOGY
Editorial
Sep 24, 2025 85 42

Charting the Future of Cancer and Organ Failure Care: A New Forum for Oncology, Nuclear Medicine and Transplantology

Zhandos Burkitbayev 1 *
1 Chairman of the Board, National Research Oncology Center, Astana, Kazakhstan* Corresponding Author
Oncology, Nuclear Medicine and Transplantology, 1(1), 2025, onmt005, https://doi.org/10.63946/onmt/17161
Online publication date: Sep 21, 2025
Publication date: Sep 24, 2025
Full Text (PDF)

ABSTRACT

This inaugural editorial introduces the new journal, "Oncology, Nuclear Medicine and Transplantology," launched by the National Research Oncology Center (NROC) in Kazakhstan. It outlines the journal's mission to serve as a pivotal interdisciplinary platform integrating these three rapidly evolving and interconnected fields. The editorial emphasizes the journal's commitment to addressing significant healthcare challenges at the national level in Kazakhstan, stimulating regional collaboration across Central Asia, and contributing to the global scientific discourse. The goal is to foster the exchange of original research, clinical experiences, and innovative practices to ultimately improve patient care and advance medical science in these critical specialties.

KEYWORDS

Oncology Nuclear Medicine Transplantology Kazakhstan

CITATION (Vancouver)

Burkitbayev Z. Charting the Future of Cancer and Organ Failure Care: A New Forum for Oncology, Nuclear Medicine and Transplantology. Oncology, Nuclear Medicine and Transplantology. 2025;1(1):onmt005. https://doi.org/10.63946/onmt/17161
APA
Burkitbayev, Z. (2025). Charting the Future of Cancer and Organ Failure Care: A New Forum for Oncology, Nuclear Medicine and Transplantology. Oncology, Nuclear Medicine and Transplantology, 1(1), onmt005. https://doi.org/10.63946/onmt/17161
Harvard
Burkitbayev, Z. (2025). Charting the Future of Cancer and Organ Failure Care: A New Forum for Oncology, Nuclear Medicine and Transplantology. Oncology, Nuclear Medicine and Transplantology, 1(1), onmt005. https://doi.org/10.63946/onmt/17161
AMA
Burkitbayev Z. Charting the Future of Cancer and Organ Failure Care: A New Forum for Oncology, Nuclear Medicine and Transplantology. Oncology, Nuclear Medicine and Transplantology. 2025;1(1), onmt005. https://doi.org/10.63946/onmt/17161
Chicago
Burkitbayev, Zhandos. "Charting the Future of Cancer and Organ Failure Care: A New Forum for Oncology, Nuclear Medicine and Transplantology". Oncology, Nuclear Medicine and Transplantology 2025 1 no. 1 (2025): onmt005. https://doi.org/10.63946/onmt/17161
MLA
Burkitbayev, Zhandos "Charting the Future of Cancer and Organ Failure Care: A New Forum for Oncology, Nuclear Medicine and Transplantology". Oncology, Nuclear Medicine and Transplantology, vol. 1, no. 1, 2025, onmt005. https://doi.org/10.63946/onmt/17161

REFERENCES

  1. Zaidi H, Ojha N, editors. Molecular Imaging and Precision Medicine: A Multidisciplinary Approach. Springer International Publishing; 2019. DOI: 10.1007/978-3-030-17715-0
  2. World Health Organization. Kazakhstan: Cancer Country Profile 2020. WHO; 2020. DOI: 10.37765/whocancer.2020.14
  3. Aimyshev T, Zhakhina G, Yerdessov S, et al. Mortality trends in Kazakhstan: insights from a million of deaths from 2014 to 2022. BMC Public Health. 2025;25(1):2312. DOI: 10.1186/s12889-025-23346-3
  4. Beyembetova A, Ablayeva A, Akhmedullin R, Abdukhakimova D, Biniyazova A, Gaipov A. National Electronic Oncology Registry in Kazakhstan: Patient’s Journey. Epidemiology and Health Data Insights. 2025;1(1):ehdi004. DOI: 10.63946/ehdi/16385
  5. Akhmedullin R, Aimyshev T, Zhakhina G, et al. In-depth analysis and trends of cancer mortality in Kazakhstan: a joinpoint analysis of nationwide healthcare data 2014-2022. BMC Cancer. 2024;24(1):1340. DOI: 10.1186/s12885-024-13128-2
  6. Kaylangan L, et al. Health System Challenges and Opportunities in Central Asia: A Scoping Review. Lancet Reg Health Eur. 2021;5:100085. DOI: 10.1016/j.lanepe.2021.100085
  7. Bikbov B, et al. Renal Replacement Therapy in Europe and Central Asia: An Analysis of Availability and Access. Kidney Int Rep. 2020;5(9):1423-32. DOI: 10.1016/j.ekir.2020.06.017
  8. GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10352):563-91. DOI: 10.1016/S0140-6736(22)01438-6
  9. Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals. 2019;12(3):114. DOI: 10.3390/ph12030114
  10. Meier RPH, et al. Transplant Immunology and Precision Medicine: The Path to Personalized Immunosuppression. J Clin Med. 2022;11(17):5042. DOI: 10.3390/jcm11175042

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.